Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:affiliatedWith |
nonsteroidal anti-inflammatory drug
|
| gptkbp:approvedBy |
gptkb:FDA
1998 |
| gptkbp:ATCCode |
gptkb:M01AH01
|
| gptkbp:brand |
gptkb:celecoxib
|
| gptkbp:chemicalFormula |
C17H14F3N3O2S
|
| gptkbp:contraindication |
history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
history of allergic reaction to NSAIDs hypersensitivity to sulfonamides |
| gptkbp:discoveredBy |
gptkb:G.D._Searle_&_Company
|
| gptkbp:drugInteraction |
gptkb:warfarin
gptkb:fluconazole lithium ACE inhibitors diuretics |
| gptkbp:eliminationHalfLife |
11 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:form |
capsule
100 mg 50 mg 200 mg 400 mg |
| gptkbp:genericAvailable |
yes
|
| https://www.w3.org/2000/01/rdf-schema#label |
Celebrex
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:marketedAs |
gptkb:Pfizer
|
| gptkbp:mechanismOfAction |
selective inhibition of COX-2 enzyme
|
| gptkbp:metabolism |
liver (CYP2C9)
|
| gptkbp:notRecommendedFor |
patients with advanced renal disease
patients with severe hepatic impairment |
| gptkbp:patentExpired |
2014
|
| gptkbp:pregnancyCategory |
C (prior to 30 weeks gestation)
D (from 30 weeks gestation) |
| gptkbp:riskFactor |
increased risk of cardiovascular events
increased risk of gastrointestinal bleeding |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
edema
headache hypertension gastrointestinal upset |
| gptkbp:usedFor |
osteoarthritis
rheumatoid arthritis acute pain ankylosing spondylitis primary dysmenorrhea |
| gptkbp:bfsParent |
gptkb:G.D._Searle_&_Company
gptkb:Pharmacia_&_Upjohn gptkb:celecoxib |
| gptkbp:bfsLayer |
6
|